Evidence map›Paper›PMID 34585143›Full record

ArticleNature reviews. Methods primers2021

Bioorthogonal chemistry.

Samuel L Scinto, Didier A Bilodeau, Robert Hincapie, Wankyu Lee, Sean S Nguyen, Minghao Xu, Christopher W Am Ende, M G Finn, Kathrin Lang, Qing Lin and 4 more

Abstract read
In one paragraph

Article in Nature reviews. Methods primers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 222 papers.

0numbers the graph read from it
0cells of the map it votes in
222citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

222 citing papers in PubMed.

  1. Review
  2. Nanorulers for Super-Resolution Microscopy.Chembiochem : a European journal of chemical biology · 2026
    Review
  3. Review
  4. Review
  5. Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. SuFEx-Enabled Reprogramming of Flavonoids for Selective α-Glucosidase Covalent Inhibition.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. ACS infectious diseases · 2026
    Article
  19. Review
  20. Article

162 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Samuel L ScintoDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE, USA.
Didier A BilodeauDepartment of Chemistry and Biomolecular Science, University of Ottawa, Ottawa, Ontario, Canada.
Robert HincapieSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-7358-4543
Wankyu LeePfizer Worldwide Research and Development, Cambridge, MA, USA.ORCID 0000-0001-9048-6398
Sean S NguyenDepartment of Chemistry, University of California, Irvine, CA, USA.ORCID 0000-0002-1801-5521
Minghao XuSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0002-7684-4926
Christopher W Am EndePfizer Worldwide Research and Development, Groton, CT, USA.
M G FinnSchool of Chemistry and Biochemistry, Georgia Institute of Technology, Atlanta, GA, USA.ORCID 0000-0001-8247-3108
Kathrin LangDepartment of Chemistry, Technical University of Munich, Garching, Germany.ORCID 0000-0002-1318-6567
Qing LinDepartment of Chemistry, State University of New York at Buffalo, Buffalo, NY, USA.ORCID 0000-0002-9196-5718
John Paul PezackiDepartment of Chemistry and Biomolecular Science, University of Ottawa, Ottawa, Ontario, Canada.
Jennifer A PrescherDepartment of Chemistry, University of California, Irvine, CA, USA.ORCID 0000-0002-9250-4702
Marc S RobillardTagworks Pharmaceuticals, Nijmegen, Netherlands.
Joseph M FoxDepartment of Chemistry and Biochemistry, University of Delaware, Newark, DE, USA.ORCID 0000-0002-8258-1640

Funding

This renovation project will create over 1455 sq. ft. of state- of-the-art reseaP20GM104316 · NIGMS · UNIVERSITY OF DELAWARE · PI SCHMITZ, KARL ROBERT · 2014 to 2024
$26.8M
Toolkit for Fast, Multipurpose and Inducible Bioorthogonal ChemistryR01GM132460 · NIGMS · UNIVERSITY OF DELAWARE · PI JOSEPH M FOX · 2019 to 2026
$4.2M
Development and Applications of Bioorthogonal Chemistry: Equipment SupplementR35GM130307 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Qing Lin · 2019 to 2026
$3.6M
Cyclopropenones to assemble, analyze, and activate biomoleculesR01GM126226 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI PRESCHER, JENNIFER · 2018 to 2021
$1.1M
NIGMS NIH HHS P20 GM104316NIGMS NIH HHS R01 GM126226NIGMS NIH HHS R01 GM132460NIGMS NIH HHS R35 GM130307
6 · The paper itself

Abstract

Bioorthogonal chemistry represents a class of high-yielding chemical reactions that proceed rapidly and selectively in biological environments without side reactions towards endogenous functional groups. Rooted in the principles of physical organic chemistry, bioorthogonal reactions are intrinsically selective transformations not commonly found in biology. Key reactions include native chemical ligation and the Staudinger ligation, copper-catalysed azide-alkyne cycloaddition, strain-promoted [3 + 2] reactions, tetrazine ligation, metal-catalysed coupling reactions, oxime and hydrazone ligations as well as photoinducible bioorthogonal reactions. Bioorthogonal chemistry has significant overlap with the broader field of 'click chemistry' - high-yielding reactions that are wide in scope and simple to perform, as recently exemplified by sulfuryl fluoride exchange chemistry. The underlying mechanisms of these transformations and their optimal conditions are described in this Primer, followed by discussion of how bioorthogonal chemistry has become essential to the fields of biomedical imaging, medicinal chemistry, protein synthesis, polymer science, materials science and surface science. The applications of bioorthogonal chemistry are diverse and include genetic code expansion and metabolic engineering, drug target identification, antibody-drug conjugation and drug delivery. This Primer describes standards for reproducibility and data deposition, outlines how current limitations are driving new research directions and discusses new opportunities for applying bioorthogonal chemistry to emerging problems in biology and biomedicine.

Identifiers

PMID34585143
PMCPMC8469592

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.